TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Evaluation of the Radiographic Efficacy of Enbrel

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject eligibility should be reviewed and documented by an appropriately qualified member of the investigator's study team before subjects are included in the study.~* Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study is a requirement for inclusion into this study.~Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study:~* Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.~* Definitive diagnosis of RA or PsA.~* Eligible for Etanercept treatment according to Summary of Product Characteristics (SmPC).~* Inclusion of subjects pretreated with other biologics other than Etanercept is possible~* One plain radiograph of hands and feet (Anteroposterior) within 3 month prior to initiation of treatment with Etanercept and one planned consecutive radiograph of hand and feet taken over 12 to 18 months according to German recommendations for patients treated with biologics.~Exclusion Criteria:~* Receipt of any investigational drug within 3 months of study inclusion.~* Exclusion Criteria according to the Enbrel® SmPC, with particular attention to:~* Hypersensitivity to the active substance (etanercept) or to any of the excipients.~* Sepsis or risk of sepsis.~* Active infections, including chronic or localised infections.~* Subjects who have received any previous treatment with etanercept~* Subjects who are investigational site staff members or subjects who are Pfizer employees directly involved in the conduct of the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with Rheumatoid Arthritis (Type: None): None
- Patients with Psoriasis Arthritis (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject must have completed Week 12 of AMB-320 (NCT00423748) or AMB-321 (NCT00423202) or must have received placebo during AMB-320 (NCT00423748) or AMB-321 (NCT00423202) and met two or more early escape criteria;~2. Subject must be competent to understand the information given in the Institutional Review Board (IRB) or Independent Ethics Committee (IEC) approved informed consent form and must sign the form prior to the initiation of any study procedures.~3. Female subject of childbearing potential must agree to use two reliable methods of contraception until study completion and for at least four weeks following their final study visit. Reliable methods include: birth control pills/implants/injections, intrauterine devices (IUDs), spermicide, diaphragms, or condoms.~Exclusion Criteria:~* Subjects must have met the exclusion criteria of the AMB-320 (NCT00423748) and AMB-321 (NCT00423202)studies. In addition, a subject who meets any one of the following criteria is ineligible for participation in the study:~  1. Subject receiving bosentan, sildenafil, or iv inotropes at any time within four weeks prior to the AMB-320/321-E Screening/Randomization Visit;~ 2. Subject receiving chronic prostanoid therapy (epoprostenol, treprostinil, iloprost, beraprost, or any other investigational prostacyclin derivative) within four weeks prior to the AMB-320/321-E Screening/RandomizationVisit;~ 3. Female subject who is pregnant or breastfeeding;~ 4. Subject with cardiovascular, liver, renal, hematologic, gastrointestinal, immunologic, endocrine, metabolic, or central nervous system disease that, in the opinion of the Investigator, may adversely affect the safety of the subject and/or efficacy of the study drug or severely limit the lifespan of the subject;~ 5. Subject who has demonstrated noncompliance with previous medical regimens;~ 6. Subject who has a recent history of abusing alcohol or illicit drugs;~ 7. Subject who has participated in a clinical study involving another investigational drug or device at any time within four weeks prior to the AMB-320/321-E Screening/Randomization Visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ambrisentan (Type: EXPERIMENTAL): 2.5, 5 or 10 mg ambrisentan

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Adaptive Physical Activity for Chronic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* evidence of stroke (ischemic or hemorrhagic) minimum 6 months prior in men or women ages 40 or older;~* residual hemiparetic gait deficits;~* already completed all conventional inpatient and outpatient physical therapy;~* ability to rise from a chair unaided and without an assistive device~Exclusion Criteria:~* cardiac history of active unstable angina, recent (less than 3 months) myocardial infarction, or congestive heart failure (NYHA category II or higher);~* orthopedic, circulatory, or chronic pain conditions restricting exercise;~* active cancer; poorly controlled hypertension ( greater than 180/100 on 2 readings separated by 5 minutes rest);~* dementia;~* severe receptive or global aphasia with inability to follow 2-step commands;~* co-morbid non-stroke neurological disorder that impairs mobility (e.g. multiple sclerosis or Parkinson's);~* untreated clinical depression;~* inability to complete the 6-Minute Walk test during baseline testing

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- APA-Stroke (Type: EXPERIMENTAL): The APA-stroke exercise program designed specifically for individuals with hemiparetic gait deficits due to stroke. These progressive exercises focus on walking, balance and weight shifting and include an exercise homework component.
- Sittercise (Type: ACTIVE_COMPARATOR): Sittercise is not stroke specific. This less vigorous exercise program consists of seated exercise, focusing on stretching to improve general range of motion and weight exercises to strengthen the trunk, arms, and legs. There is no assigned exercise homework associated with this group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Non-lactating female subjects (Sexually active women must be postmenopausal, surgically sterile, or practicing an effective method of birth control \[e.g., prescription oral contraceptives, contraceptive injections, intrauterine device, double barrier method, contraceptive patch, male partner sterilization\] before entry and throughout the trial. Female patients of childbearing potential must have a negative pregnancy test at screening.)~* Completion of the expected double-blind treatment period of the pivotal Tapentadol (CG5503) Phase 3 trials in osteoarthritis (R331333-PAI-3008, KF5503/11) or low back pain (R331333-PAI-3011, KF5503/23), or completion of the 1-year treatment period of the safety CG5503 Phase 3 trial in the non-European sites (R331333-PAI-3007, KF5503/24)~* Must be willing to take Tapentadol (CG5503) extended release (ER) and the rescue medication supplied for the duration of the trial~Exclusion Criteria:~* History of alcohol and/or drug abuse, life-long history of seizure disorder or epilepsy, any of the following within the past year: mild/moderate traumatic brain injury, stroke, transient ischemic attack, or brain neoplasm~* Severe traumatic brain injury within the past 15 years~* Uncontrolled hypertension (repeated systolic blood pressure \>160 mmHg or diastolic blood pressure \>95 mmHg)~* Severely impaired renal function~* Moderately or severely impaired hepatic function~* Patients taking neuroleptics, monoamine oxidase inhibitors, or tricyclic antidepressants within 14 days prior to screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): Tapentadol (CG5503) Extended Release (ER) 100 150 200 250 mg oral tablet twice daily for 52 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meets current Diagnostic and Statistical Manual for Mental Disorders-Fourth Edition (DSM-IV) diagnostic criteria for AD and demonstrates serious behavioral problems. Diagnosis confirmed by Autism Diagnostic Interview- Revised (ADI-R)~* CGI score \> = 4 AND and Aberrant Behavior Checklist (ABC) Irritability/Agitation subscale score \> = 18 at screening and baseline (randomization)~* Mental age of at least 18 months~* Male or female 6 to 17 years of age, inclusive, at the time of randomization~Exclusion Criteria:~* Patients considered treatment resistant to neuroleptic medication based on lack of therapeutic response to 2 different neuroleptics after treatment of at least 3 weeks each.~* Patients previously treated and not responding to aripiprazole treatment~* The patient is currently diagnosed with another disorder on the autism spectrum, including PDD-NOS, Asperger's Disorder, Rett's Disorder, Fragile-X Syndrome or Childhood Disintegrative Disorder~* Current diagnosis of bipolar disorder, psychosis, or schizophrenia, or major depression~* A seizure in the past year~* History of severe head trauma or stroke~* Patients undergoing non-pharmacologic therapies (e.g., psychotherapy, behavioral modification) must have started at least 2 months prior to the initial screening visit and must remain in a consistent treatment program for the duration of the study.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- A1 (Type: EXPERIMENTAL): Active Abilify
- A2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women 18 years or older with metastatic or locally advanced disease, not amenable to curative therapy~* Confirmed diagnosis of HR+/HER2- breast cancer~* Any menopausal status~* Progressed within 12 months from prior adjuvant or progressed within 1 month from prior advanced/metastatic endocrine breast cancer therapy~* On an LHRH agonist for at least 28 days, if pre-/peri-menopausal, and willing to switch to goserelin (Zoladex ®) at time of randomization.~* Measurable disease defined by RECIST version 1.1, or bone-only disease~* Eastern Cooperative Oncology Group (ECOG) PS 0-1~* Adequate organ and marrow function, resolution of all toxic effects of prior therapy or surgical procedures~* Patient must agree to provide tumor tissue from metastatic tissue at baseline~Exclusion Criteria:~* Prior treatment with any CDK inhibitor, fulvestrant, everolimus, or agent that inhibits the PI3K-mTOR pathway~* Patients with extensive advanced/metastatic, symptomatic visceral disease, or known uncontrolled or symptomatic CNS metastases~* Major surgery or any anti-cancer therapy within 2 weeks of randomization~* Prior stem cell or bone marrow transplantation~* Use of potent CYP3A4 inhibitors or inducers

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): Given until objective progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent, whichever occurs first.
- Arm B (Type: ACTIVE_COMPARATOR): Given until objective progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent, whichever occurs first.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ARTEMIS Peanut Allergy In Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Age 4 to 17 years, inclusive~* Clinical history of allergy to peanuts~* Serum SPT ≥ 3 mm greater than control and/or psIgE ≥ 0.35 kUa/L~* Dose limiting symptoms after consuming a single dose of peanut protein ≤ 300 mg~* Written informed consent from the subject's parent/guardian~* Written assent from the subject as appropriate (per local regulatory requirements)~* Use of effective birth control by sexually active female subjects of childbearing potential~Key Exclusion Criteria:~* History of cardiovascular disease, including uncontrolled or inadequately controlled hypertension~* History of severe asthma (NHLBI criteria steps 5 or 6), or mild to moderate asthma (2007 NHLBI criteria steps 1-4) that is uncontrolled or difficult to control~* History of severe or life threatening episode of anaphylaxis or anaphylactic shock within 60 days of screening~* History of eosinophilic esophagitis (EoE), other eosinophilic gastrointestinal disease, chronic, recurrent, or severe gastroesophageal reflux disease (GERD), symptoms of dysphagia or recurrent gastrointestinal symptoms of undiagnosed etiology~* History of a mast cell disorder, including mastocytosis, urticaria pigmentosa, chronic idiopathic or chronic physical urticaria beyond simple dermatographism (e.g., cold urticaria, cholinergic urticaria), and hereditary or idiopathic angioedema~* Any other condition that, in the opinion of the Investigator, precludes participation for reasons of safety

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- AR101 (Type: ACTIVE_COMPARATOR): AR101 powder provided in capsules \& sachets
- Placebo (Type: PLACEBO_COMPARATOR): Placebo powder provided in capsules \& sachets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Pediatric Aquatic Therapy in Children With Spastic Cerebral Palsy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Children diagnosed as cerebral palsy, spastic type~2. Gross Motor Functional Classification (GMFCS) level II-IV~3. Age: 4-12 y/o~4. Informed consent by parents~5. Modified Ashworth score 2 or3~6. If participant history of epilepsy ,well controlled by medication~Exclusion Criteria:~1. History of psychiatric diseases~2. Poor controlled epilepsy~3. Received botox injection or surgery in recent three months~4. Children diagnosed as attention deficit hyperactivity disorder(ADHD) or autism~5. Severe mental retardation~6. Active infection (Body temperature \> 100°F)~7. Communication problems~8. Bowel incontinence~9. Bladder incontinence~10. Severe cardiovascular disease~11. Infectious skin conditions and open wound~12. Nasogastric tubes or gastrostomy tubes~13. Colostomy ,urostomy or ileostomy bags~14. Acute orthopedic injury with pain and instability~15. Diabetes~16. Chlorine sensitivity~17. Latex allergies~18. Tracheostomy

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- pediatric aquatic therapy (Type: EXPERIMENTAL): The children of the PAT group participated in a 1 hour/time, twice-per-week, 12-week, PAT program in addition to conventional rehabilitation programs
- conventional therapy (Type: NO_INTERVENTION): The children included in the control group continued with their original rehabilitation programs

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Different Doses of Roxadustat Treatment for Anemia in Peritoneal Dialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult patients diagnosed with Chronic kidney disease stage 5~2. Maintenance on PD for more than three months.~3. Weight between 45Kg and 110Kg~4. Renal anemia, and hemoglobin between 90g/L and 120g/L~5. Stop taking erythropoietin for enough time （erythropoietin treatment discontinuation for ≥3 days if using erythropoietin of 3000U single strength, or ≥7 days if using erythropoietin of 10000U single strength） or free of erythropoietin use~6. Signed the informed consent.~7. Willing to follow the study procedure~Exclusion Criteria:~1. Hematologic malignancy or aplastic anemia.~2. Blood loss or hemolysis.~3. Taking roxadustat, or Allergy or intolerance to roxadustat~4. Severe liver injury or active hepatitis.~5. Pregnancy or breastfeeding~6. Cancer, receiving radiotherapy and chemotherapy within 6 months.~7. Refractory hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- standard roxadustat dosage group (Type: EXPERIMENTAL): Peritoneal dialysis patients diagnosed with renal anemia will receive standard dosage of roxadustat according to weight.
- lower roxadustat dosage group (Type: EXPERIMENTAL): Peritoneal dialysis patients diagnosed with renal anemia will receive lower dosage of roxadustat according to weight.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study in Adult Patients With Moderate to Severe Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects between 18-75 years of age (inclusive), male or female, at the time of informed consent~* Moderate to severe atopic dermatitis~* Capable of providing a signed and dated informed consent form indicating the subject has been informed of all pertinent aspect of the study~Exclusion Criteria:~* Subjects with historical or current evidence of clinically significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, gastrointestinal, urogenital, nervous system, musculoskeletal, skin, sensory, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities that are uncontrolled. Significant is defined as any disease that, in the opinion of the Investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study~* Subject has a current diagnosis of other active skin disease (e.g., psoriasis or lupus erythematosus) or skin infection (bacterial, fungal, or viral) that may affect the evaluation of atopic dermatitis~* Subject has a severe comorbidity that may require systemic steroids therapy or other interventions or requires active frequent monitoring (e.g., unstable chronic asthma)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Active Comparator: SHR0302 dose A (Type: ACTIVE_COMPARATOR): Participants randomized in this arm will receive dose A of SHR0302 until end of study at week 12.
- Active Comparator: SHR0302 dose B (Type: ACTIVE_COMPARATOR): Participants randomized in this arm will receive dose B of SHR0302 until end of study at week 12.
- Placebo Comparator: Placebo (Type: ACTIVE_COMPARATOR): Participants randomized in this arm will receive Placebo of SHR0302 until end of study at week 12.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete